mRNA lipid nanoparticles induce immune tolerance to treat human diseases-Reference-Cited by-同舟云学术

mRNA lipid nanoparticles induce immune tolerance to treat human diseases

Published:2023-04-01 Issue:2 Volume:3 Page:180-183
ISSN:2749-9642
Container-title:Medical Review
language:en
Short-container-title:

Author:

Cao Wei¹²,Xia Tian¹²³^ORCID

Affiliation:

1. Translational Medical Center, Zhengzhou Central Hospital, Zhengzhou University , Zhengzhou , Henan Province , China

2. Henan International Joint Laboratory of Bioconjugation and Protein Chemistry , Zhengzhou , Henan Province , China

3. Division of NanoMedicine, Department of Medicine , University of California , Los Angeles , CA , USA

Abstract

Abstract Rapid developments in the coronavirus disease 2019 (COVID-19) mRNA vaccine showcased the power of lipid nanoparticle (LNP) delivery systems in fighting infectious diseases. In addition, mRNA therapeutics are also in development for cancer immunotherapy. Recently, mRNA therapy has been expanded to induce immune tolerance, the opposite of immune-boosting effects, to treat diseases involving enhanced immune responses including allergies and autoimmune diseases. mRNA LNPs have been used to treat peanut allergy by us and autoimmune experimental autoimmune encephalomyelitis by Ugur Sahin. It is expected that more and more research is going to delve into the immune tolerance field for allergies and autoimmune diseases, where effective therapies are in short supply.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/mr-2023-0008/pdf

Reference10 articles.

1. Kumar, A, Blum, J, Thanh Le, T, Havelange, N, Magini, D, Yoon, IK. The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discov 2022;21:333–4. https://doi.org/10.1038/d41573-022-00035-z.

2. Lorentzen, CL, Haanen, JB, Met, O, Svane, IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol 2022;23:e450–8. https://doi.org/10.1016/s1470-2045(22)00372-2.

3. Krienke, C, Kolb, L, Diken, E, Streuber, M, Kirchhoff, S, Bukur, T, et al.. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021;371:145–53. https://doi.org/10.1126/science.aay3638.

4. Liu, Q, Wang, X, Liao, YP, Chang, CH, Li, J, Xia, T, Nel, AE. Use of a liver-targeting nanoparticle platform to intervene in peanut-induced anaphylaxis through delivery of an Ara h2 T-cell epitope. Nano Today 2022;42:101370. https://doi.org/10.1016/j.nantod.2021.101370.

5. Liu, Q, Wang, X, Liu, X, Kumar, S, Gochman, G, Ji, Y, et al.. Use of polymeric nanoparticle platform targeting the liver to induce Treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization model. ACS Nano 2019;13:4778–94. https://doi.org/10.1021/acsnano.9b01444.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid Nanoparticles Elicit Reactogenicity and Sickness Behavior in Mice Via Toll-Like Receptor 4 and Myeloid Differentiation Protein 88 Axis;ACS Nano;2024-08-26

2. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment;Signal Transduction and Targeted Therapy;2024-02-21

3. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity;Vaccines;2024-02-12

4. Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance;Nanomaterials;2023-12-26